Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs glipizide in type 2 diabetes with end-stage renal disease on dialysis
2007-003529-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Change in HbA1c from baseline at 54 weeks (sitagliptin arm), Safety and tolerability of sitagliptin and 5 more. Started Aug 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-003529-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003529-26.